Adicet Bio's Lupus Trial Delivers 100% Response, Setting Stage For Phase 2
Adicet Bio Inc. (NASDAQ:ACET) shares fell Tuesday after the biotechnology company priced an $80 million direct offering, even as early safety and efficacy data from its Phase 1 trial of ADI-001 in autoimmune diseases showed encouraging signs.
Benzinga ·